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Abstract
Retinoids are used clinically to treat a number of hyper-proliferative disorders and have been shown in experimental
animals to attenuate vascular occlusive diseases, presumably through nuclear receptors bound to retinoic acid response
elements (RARE) located in target genes. Here, we show that natural or synthetic retinoids rapidly induce mRNA and protein
expression of a specific isoform of A-Kinase Anchoring Protein 12 (AKAP12b) in cultured smooth muscle cells (SMC) as well
as the intact vessel wall. Expression kinetics and actinomycin D studies indicate Akap12b is a retinoid-induced, immediate-
early gene. Akap12b promoter analyses reveal a conserved RARE mildly induced with atRA in a region that exhibits hyper-
acetylation. Immunofluorescence microscopy and protein kinase A (PKA) regulatory subunit overlay assays in SMC suggest a
physical association between AKAP12b and PKA following retinoid treatment. Consistent with its designation as a tumor
suppressor, inducible expression of AKAP12b attenuates SMC growth in vitro. Further, immunohistochemistry studies
establish marked decreases in AKAP12 expression in experimentally-injured vessels of mice as well as atheromatous lesions
in humans. Collectively, these results demonstrate a novel role for retinoids in the induction of an AKAP tumor suppressor
that blocks vascular SMC growth thus providing new molecular insight into how retiniods may exert their anti-proliferative
effects in the injured vessel wall.
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Introduction
Vascular SMC are normally quiescent and express a repertoire
of cytoskeletal and contractile proteins that subserve functions
related to contractile tone and the maintenance of vascular
integrity. A variety of vasculopathies shift the phenotype of SMC
from one of quiescence and contractile competence to prolifera-
tion, migration, matrix production, and attenuated expression of
contractile proteins [1]. A variety of therapeutic molecules have
been shown to attenuate such phenotypic switching including a
class of compounds known as retinoids [2]. Retinoids encompass
synthetic and natural derivatives of retinol (vitamin A) that have
found clinical utility in the management of several human hyper-
proliferative disorders [3,4]. Cultured SMC treated with the
natural retinoid, all-trans retinoic acid (atRA) or its isoform (e.g.,9 -
cis RA), consistently show reduced growth potential during growth
factor stimulation [5–9] and in some cases restoration of the
contractile phenotype [10]. Moreover, a variety of animal models
of vascular disease have been used to demonstrate retinoid-
mediated decreases in neointimal burden and increases in vessel
patency [11–19]. Thus, retinoids represent a viable class of
therapeutic molecules for the potential management of vascular
occlusive disorders.
Retinoids exert their pleiotropic actions by binding ligand-
activated nuclear receptors that control gene expression [20]. One
logical approach to begin elucidating the mechanisms underlying
retinoid action in the vessel wall is to define retinoid-responsive
target genes. We previously performed a modified suppression
subtractive hybridization screen in cultured SMC for the
identification of atRA-responsive genes [21]. One of the genes
reported to be induced by atRA was Src-Suppressed C Kinase
Substrate (SSeCKS), the rodent ortholog [22] of human gravin
[23] encoding for an A-kinase anchoring protein (AKAP).
SSeCKS (official gene symbol, AKAP12) binds and localizes a
number of signaling proteins including PKA, protein kinase C
(PKC), calmodulin, and the b2-adrenergic receptor [24,25]. The
assembly of such signaling complexes is linked to AKAP12
activities involved in growth suppression, actin cytoskeletal
remodeling, and adrenergic signal transduction [24]. The growth
suppressive activities of AKAP12, together with its attenuated
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neoplasms, have led to the concept of AKAP12 being a tumor
suppressor gene [24]. Further evidence for this hypothesis was
recently demonstrated in AKAP12 knockout mice, which exhibit
prostatic hyperplasia and focal dysplasia [26].
Previous studies have documented AKAP12 expression in SMC
[21,27,28], but the regulatory control of its induction and function
in SMC have not been well characterized. Moreover, since the
AKAP12 locus comprises three independent transcription units,
each under control of a unique promoter [29], the AKAP12
isoform responsive to the action of retinoids is unknown. In this
report, we show that the AKAP12b isoform is rapidly and highly
induced by both natural and synthetic retinoids. We further show
that AKAP12b associates with PKA and mediates increases in
activity of at least one downstream target of PKA. Acute or
inducible over-expression of AKAP12b attenuates SMC growth in
human and rodent SMC model systems. Finally, we demonstrate
decreases in AKAP12 expression in vascular lesions where hyper-
proliferative activity exists. Our results establish AKAP12b as a
novel retinoid-responsive tumor suppressor gene, making it an
attractive target for therapy in a variety of disease contexts,
including vascular occlusive diseases.
Results
atRA Induces a Specific Isoform of AKAP12 in Multiple
Species of Vascular SMC
In the course of defining a novel retinoid-response gene set, we
identified a tumor suppressor gene called AKAP12 that was
induced with atRA in RASMC [21]. To extend these results, we
performed Northern blotting on multiple sources of SMC treated
for varying times with atRA. Results in Figure 1A reveal a rapid
induction of Akap12 mRNA in the rat PAC1 SMC line, RASMC,
and HCASMC. The increase in Akap12 mRNA was also seen with
13 cis-RA stimulation, but not with agonists to PPAR gamma (data
not shown). On the other hand, agonists to retinoic acid receptor
(RAR) and retinoid X receptor (RXR) each elicited increases in
Akap12 mRNA (Figure 1B). The increase in Akap12 mRNA with
atRA was dose-dependent (Figure 1C) and RNA polymerase II-
dependent as evidenced by complete suppression with actinomycin
D treatment (Figure 1D). atRA-stimulated Akap12 mRNA was not
universally seen as some cell types (L6 and BC3H1 myoblasts)
failed to show increases with retinoid treatment (data not shown).
Akap12’s rapid expression kinetics in SMC following retinoid
stimulation, its dependence on de novo mRNA synthesis, and its
independence for de novo protein synthesis [21] indicate that this
tumor suppressor is a retinoid-induced, immediate-early gene.
We recently defined the Akap12 genomic landscape and
discovered that three independent promoters direct expression of
three Akap12 isoforms (Figure 2A and [29]). To ascertain which of
the Akap12 isoforms is targeted for induction with retinoids, exon-
specific probes to each Akap12 isoform were designed and applied
to samples of RNA from atRA-stimulated PAC1 SMC. Results
indicate that atRA specifically targets the Akap12b isoform with
expression kinetics nearly identical to those observed with a probe
common to all Akap12 isoforms (compare Figure 1A with
Figure 2B). Similar kinetics of Akap12b induction was seen with
the synthetic retinoid AM80 (Figure S1A). mRNA kinetic studies
suggest that the half-life of retinoid-induced Akap12b is on the
order of 3 hr (Figure S1B).
To determine whether retinoids elicit Akap12b-specific induc-
tion in the intact vessel wall, we administered atRA or corn oil to
adult mice by oral gavage and measured serum retinoid levels as
well as Akap12 isoforms in vascular tissue (enriched for SMC only)
using PCR primers specific for Akap12a or Akap12b. No detectable
levels of retinoids were seen in corn oil treated mice. However,
consistent with a previous report in the rat [11], atRA-treated mice
exhibited therapeutic levels of atRA (5144.86701 ng/ml), 13-cis
Figure 1. Retinoid-induced expression of Akap12. Northern blot analyses of Akap12 expression showing (A) time-dependent increases
following atRA stimulation in the indicated cells; (B) retinoid receptor agonist-induced Akap12 mRNA in PAC1 SMC; (C) atRA dose-dependent increase
in PAC1 SMC; and (D) RNA polymerase II-dependent increase in PAC1 SMC treated with atRA in absence or presence of actinomycin D (Act-D).
Equivalent total RNA loading is indicated with either ethidium bromide staining of 18 S rRNA or expression levels of glyceraldehyde phosphate
dehydrogenase (Gapdh).
doi:10.1371/journal.pone.0018538.g001
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following atRA administration. As with in vitro cell culture data,
SMC- enriched vascular tissue exposed to atRA showed little
change in Akap12a mRNA but clear increases in the Akap12b
isoform (Figure 2C). A similar induction of AKAP12 protein was
observed in vascular SMC-enriched aortic tissue (Figure 2D).
Taken together, results indicate rapid and specific induction of the
Akap12b isoform upon treatment with retinoids in various SMC
culture models as well as mouse SMC of the vessel wall.
Akap12b Promoter Harbors an Atypical RARE
We previously characterized the Akap12b promoter and showed
basal activity in a variety of cell types, including SMC [29]. To
determine whether any conserved RARE is present in the Akap12b
promoter, we compared the rat, mouse, and human Akap12b
promoters for conserved RAREs based on a base frequency table
of 67 experimentally-validated RAREs [4]. We found an RARE
located -2,534 bp upstream of the annotated start site of
transcription (see GenBank Accession number AY695060) and
the sequence of this RARE indicates that it is a direct repeat (DR)-
2 RARE, where each half site is spaced by two nucleotides
(Figure 3A). Extensive transient and stable transfections in SMC
treated with atRA revealed weak activation of the native Akap12b
promoter constructs carrying the RARE (data not shown). To
determine whether the Akap12b RARE is more responsive to atRA
in isolation, we multimerized the sequence and placed it upstream
of a thymidine kinase minimal promoter (Figure 3A). Robust
activation of a DR-5 RARE from the Rarb gene is evident with
atRA stimulation (data not shown). However, the Akap12b RARE
is only weakly (,2-fold) activated with atRA stimulation
(Figure 3B). This level of activation is comparable to that seen
with carbonic anhydrase (Ca2), a known retinoid responsive target
gene containing a similar DR-2 RARE as that seen in the Akap12b
RARE [30] (Figure 3B). Mutagenesis experiments failed to reveal
a clear-cut dependence on the DR-2 RARE (data not shown),
likely because of the weak level of induction. Nevertheless, ChIP
assays consistently showed enrichment for acetylated histone H3
within the region encompassing the DR-2 RARE, suggesting that
the chromatin landscape is modified to a transcriptionally
competent state with retinoid stimulation (Figure 3C). Interesting-
ly, we saw little evidence of retinoic acid receptor alpha
enrichment in this region consistent with the weak activation of
the RARE. These results reveal a mild, though consistent,
activation of the Akap12b RARE and a transcriptionally
competent chromatin landscape following atRA stimulation.
atRA-Induced AKAP12 Protein Expression and
Association with PKA
To assess expression kinetics of AKAP12 protein, we performed
Western blotting on extracts of PAC1 SMC treated with atRA.
Results demonstrated increases in AKAP12b protein as early as 12
hr post-atRA treatment with levels gradually decreasing at 72 hr
(Figure 4A). Similar induction of AKAP12 protein was seen with
AM80 treatment (Figure S2). Virtually no change in expression of
smooth muscle calponin (CNN1) was seen with atRA treatment
(Figure 4A). Immunofluorescence microscopy of PAC1 SMC
showed atRA increases AKAP12 around the nucleus and at the
periphery of the cell (Figure 4B, panels a versus d). The expression
of the regulatory II (RII) alpha subunit of PKA, to which AKAPs
bind [31], displayed a perinuclear localization of expression with
little to no changes in level or cellular distribution following atRA
stimulation (Figure 4B, panels b versus e, and data not shown).
Importantly, the perinuclear expression of AKAP12 and RII alpha
appeared to overlap in the perinuclear region only (Figure 4B,
panels c versus f). To extend these data further, we performed an
RII alpha overlay assay in PAC1 SMC treated with either DMSO
vehicle or atRA for 12 and 24 hr. These results demonstrated a
dramatic induction of an AKAP12b-radiolabeled RII alpha
complex with atRA treatment (Figure 4C). Several lower
molecular weight AKAPs showed little, if any, induction
suggesting that the stimulatory effect of atRA is specific to the
AKAP12 locus in SMC. Interestingly, AKAP12b over-expression
Figure 2. atRA-induced expression of the Akap12b isoform. (A) Schematic of Akap12 locus comprising three alternate start sites of
transcription (bent arrows) under separate promoter control with proper nomenclature for exons. (B) Northern blotting of PAC1 SMC treated with
atRA for the indicated times and using exon-specific probes to each Akap12 isoform. Testes RNA (Te) is included as a positive control for the Akap12a
and Akap12c isoforms. (C) Northern blotting with isoform-specific PCR primers on aortic tissue from mice treated with either corn oil or atRA for 24 hr.
(D) Western blotting with antisera to AKAP12 on aortic tissue from mice treated with either corn oil or atRA for 24 hr suggests a similar elevation of
AKAP12b protein (see also Figure 4A).
doi:10.1371/journal.pone.0018538.g002
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CREB activation as well as elevated phosphorylation of vasodi-
lator-stimulated phosphoprotein (Figure S3). These results extend
our Akap12bmRNA expression studies to the protein level and
indicate a close association between AKAP12b and PKA-
mediated signaling in SMC.
AKAP12b Overexpression Attenuates SMC Growth
Studies in cancer cell lines suggest that both AKAP12a and b
attenuate proliferation [24,32]. To evaluate the potential of
AKAP12b over-expression to elicit growth suppressive properties
in the context of SMC, we generated PAC1 SMC clones stably-
transfected with doxycycline-inducible AKAP12b. Treatment of
control (empty vector alone) stable cell lines with doxycycline
showed no change in cell growth indicating there was no intrinsic
growth inhibitory effects of doxycycline in these cells at a
concentration of 1 mg/ml (data not shown). Cells carrying a
Myc-tagged AKAP12b transgene showed robust expression of
AKAP12b after 1 day of doxycycline treatment with levels
AKAP12b persisting over the entire time course of study
(Figure 5A). Importantly, we showed doxycycline-dependent cell
growth inhibition in three independent AKAP12b expressing cell
lines as compared to the same cells where AKAP12b was not over-
expressed (Figure 5B). To evaluate the effects of AKAP12b in
human SMC, we transduced HCASMC with adenovirus carrying
AKAP12b under control of the CMV promoter (Ad-AKAP12b).
Efficient over-expression of AKAP12b was shown over a 5 day
time course by Western blot analysis (Figure 5C). Similar to results
seen in stably-transfected PAC1 SMC, HCASMC over-expressing
AKAP12b showed a significant reduction in cell number
(Figure 5D). These results are consistent with the known growth
suppressive effects of AKAP12 and suggest that retinoids may
inhibit SMC growth, at least in part, through the induction of
AKAP12b. Attempts to knock down retinoid-induced levels of
AKAP12bmRNA were unsuccessful thus precluding rescue studies
relating to SMC proliferation (data not shown).
Expression of AKAP12 in Vascular Lesions
A hallmark of a tumor suppressor gene is reduced expression
within tissues associated with accelerated growth. To examine
expression of AKAP12 in vascular lesions associated with SMC
growth, we used a mouse model of neointimal formation [33]
combined with Ki-67 staining. IgG control stained vessels revealed
no background staining (Figure S4). Uninjured carotid arteries
exhibit abundant AKAP12 and no cell proliferation consistent
with the contractile phenotype (Figure 6A, 6D and Figure S4).
When such vessels are subject to a partial ligation injury [33], Ki-
67 positive cells increase in the media and neointima of 1 week
(20.87% Ki-67 positive cells, Figure 6E) and 3 week (4.5% Ki-67
positive cells, Figure 6F) vessels. In general, and consistent with
data in the cancer field [34], Ki-67 positive cells showed weak
AKAP12 staining, especially in 3 week injured vessels where a
prominent neointima is manifest (Figure 6E, 6F). We also noted
dramatic reductions in AKAP12 staining in the vessel wall
following complete ligation of the carotid artery (Figure S4).
Importantly, human atherosclerotic lesions showed virtually no
AKAP12 expression within the neointima (Figure 7A, 7D). Such
low AKAP12 expression correlates with reductions in CNN1
(Figure 7B, 7E), a SMC differentiation marker known to be
reduced in atherosclerosis [35]. Similar findings have been seen in
multiple independent atheromas of varying severity (data not
shown). To rule out an intrinsic loss in immunoreactivity within
the neointima of these vessels as an explanation for the loss in
AKAP12 and CNN1 expression, adjacent sections were analyzed
for macrophage content using the Ham56 antibody (Figure 7C,
7F). These results showed immunoreactive macrophages within
the neointima indicating that loss in AKAP12 and CNN1 within
the neointima is not a consequence of some intrinsic defect in
Figure 3. Akap12b RARE transcriptional activity and chromatin remodeling. (A) Schematic of multimerized RARE (located on antisense stand
-2.5 kb upstream of Akap12b promoter; see coordinates 2866-2879 in GenBank Accession number AY695060) cloned upstream of a thymidine kinase
(tk) luciferase expression plasmid. The two half-sites of the RARE are underlined. (B) PAC1 SMC transfected with luciferase reporter plasmids
containing indicated multimerized RARE sequences in absence or presence of atRA. Data are normalized to the Renilla control plasmid and represent
the average of three replicates. Data are representative of several similar transient transfections in PAC1 SMC. (C) ChIP assay of PAC1 SMC treated with
DMSO or atRA for 6 hr using the indicated antibodies. Similar enrichment of acetylated histone H4 was seen with atRA stimulation (data not shown).
doi:10.1371/journal.pone.0018538.g003
Retinoids Induce AKAP12b
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18538immunolocalization. Thus, AKAP12 expression is attenuated in
both experimental and human conditions of neointimal formation
and such decreases appear to correlate with elevated SMC
proliferation.
Discussion
Over 50 AKAPs have been defined in the human genome.
AKAP functions include the ability to compartmentalize multi-
protein complexes in order to specify unique spatio-temporal
signaling events involving PKA and other signaling moieties [31].
Here, we show that the natural retinoid, atRA, and several
synthetic retinoids elicit rapid and robust induction of a specific
isoform of AKAP12 (AKAP12b) in vascular SMC. The increase in
AKAP12b is also seen in intact vascular tissue exposed to
therapeutic levels of atRA. Although we identified a conserved
DR2-RARE located in the proximal Akap12b promoter, transient
and stable transfection studies revealed only weak (,2-fold)
activation of the Akap12b RARE with retinoid stimulation.
Nevertheless, actinomycin D and ChIP assays suggest that retinoid
signaling converges at the Akap12b promoter to effect gene
transcription. A sensitive assay that detects pan-AKAP interactions
with the PKA regulatory subunit II alpha indicates that AKAP12
is the only AKAP in SMC exhibiting dramatic increases in
expression with retinoid treatment. Directed AKAP12b expression
resulted in enhanced PKA activities and attenuated SMC growth.
Finally, mouse and human vascular occlusive diseases were
associated with reduced AKAP12 expression. Together, these
studies establish AKAP12b as a strategic target of retinoid
signaling thus providing a framework for further evaluation of
this retinoid-AKAP12 axis in vascular SMC growth control and
perhaps other cell types responsive to retinoid signaling.
AKAP12 (aka SSeCKS and Gravin) has demonstrable growth
suppressive properties and is down-regulated in a variety of human
neoplasms supporting the idea that AKAP12 is a bonafide tumor
suppressor gene [32,34,36–40]. However, there is little information
on the role of AKAP12 in non-neoplastic cell growth inhibition.
Here, we demonstrate that the AKAP12b isoform reduces human
and rodent vascular SMC growth and that such growth inhibition
correlates with elevated PKA activity. Previous studies have
demonstrated PKA-mediated signaling in the inhibition of vascular
SMC growth as well as neointimal formation [41–43]. The precise
signaling mechanisms underlying PKA-mediated SMC growth
inhibition are unknown but likely relate to PKA redistribution
within cells via AKAPs such as AKAP12. In this regard, we and
others have demonstrated context-dependent and isoform-specific
localization of AKAP12 within cells [29,44,45]. Interestingly, results
shown in this report suggest that retinoid-induced AKAP12
concentrates in the peri-nuclear region in close proximity to PKA
(Figure 4B). It is possible that such peri-nuclear localization of PKA
may direct nuclear events such as the phosphorylation of CREB,
which is known in some contexts to mediate SMC growth inhibition
[46]. Further work is necessary to determine whether retinoid
signaling via AKAP12 exerts effects on transcription factors, such as
CREB, that may mediate SMC growth suppression. In this context,
it will be informative to interrogate CREB factor binding, genome
wide, following atRA stimulation of SMC to identify potentially
important downstream target genes that may mediate AKAP12-
dependent SMC growth inhibition.
Figure 4. Retinoid-induced AKAP12 protein expression. (A) Western blot of AKAP12 (upper) and smooth muscle calponin (CNN1, lower)
protein in PAC1 SMC treated with atRA for the indicated times. The two major isoforms of AKAP12 (290 and 280 kDa) run close together in the
indicated immunoblot with the lower band representing the AKAP12b isoform (the upper AKAP12a protein can be faintly seen in the DMSO control
lane). (B) Immunofluorescence microscopy of PAC1 SMC treated with DMSO vehicle (panels a–c) or atRA (panels d–f) for 24 hr using antibodies to
AKAP12 (panels a and d) or the RII alpha subunit of PKA (panels b and e). Merged images of AKAP12 and the RII alpha subunit are indicated in panels
c and f. Note the perinuclear overlap in expression of AKAP12 and RII alpha in panel f. Magnification is 4006. These studies are representative of
multiple independent experiments using a variety SMC cultures from different species. (C) RII overlay assay showing the massive and specific
induction of AKAP12b with atRA treatment. Protein extracts of PAC1 SMC treated with DMSO or atRA for the indicated times were resolved in a
polyacrylamide gel and processed for the radiolabeled RII alpha subunit overlay as described in Materials and Methods. Note the presence of multiple
AKAPs in these extracts that show little if any induction with atRA.
doi:10.1371/journal.pone.0018538.g004
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PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18538Figure 5. AKAP12b over-expression attenuates SMC growth. (A) Western blot of protein extracts taken from a clone of PAC1 SMC carrying a
Myc-tagged AKAP12b transgene stimulated with or without doxycycline (1 mg/ml). Beta actin immunoblot verifies equal protein loading. (B) Parallel
dishes of cells carrying Myc-tagged AKAP12b transgene stimulated with or without doxycycline (1 mg/ml) were manually counted with a
hemocytometer at the indicated times. Only trypan blue excluding cells were counted. Data are the mean 6 SEM of three replicates per time point
for each cell line. All three clones carrying AKAP12b showed statistically significant decreases in growth beginning 3 days following Dox stimulation.
(C) Western blot showing increases in AKAP12 protein expression within cultured HCASMC transduced with either Ad-AKAP12b (+) or a CMV-driven
LacZ adenovirus (2). Blot is representative of two independent experiments. Alpha tubulin immunoblot verifies equal protein loading. (D) Parallel
cultures of similarly transduced HCASMC were analyzed for growth over a 5 day period as in panel B. AKAP12b-expressing HCASMC (closed circles)
exhibited a statistically significant decrease in growth beginning 3 days following adenoviral transduction as compared to LacZ control cultures
(closed squares). Result is representative of two independent experiments performed by different investigators.
doi:10.1371/journal.pone.0018538.g005
Figure 6. Vascular injury-induced Ki-67 and decrease in AKAP12 expression. Uninjured right carotid artery (panels A, D) or partial ligation
of left carotid artery one week (panels B, E) and three weeks (panels C, F) post-injury were stained for either AKAP12 (red stain in panels A-C) or Ki-67
(brown stain in panels D–F). Arrows point to cells showing clear positivity for Ki-67 and reduced AKAP12. The dotted line in panels C and F represent
the full thickness of the neointima. Note the marked decrease in AKAP12 staining after three weeks of the partial ligation injury. Original
magnifications were 6006.
doi:10.1371/journal.pone.0018538.g006
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inhibition. Although several tumor suppressor genes have been
shown to be retinoid-inducible [47], none exhibit the rapid onset
and high level induction observed with AKAP12b. It will therefore
be informative to test whether treating neoplastic cells with natural
or synthetic retinoids induces AKAP12b to counter-balance the
documented silencing of the AKAP12a isoform [39,40].
The Akap12 locus comprises three independent promoters
controlling unique isoforms with distinct intracellular localizations
[29]. Such diversity in Akap12 isoform expression exemplifies the
complexity of the human genome with a total gene count only
mildly greater than that in simpler vertebrate species. Limited
information exists with respect to differential control of each
Akap12 promoter with virtually all work reporting effects on the
proximal, Akap12a promoter. Initial studies demonstrated the
importance of serum response factor-binding CArG boxes in the
regulation of Akap12a promoter activity [48]. Adjacent GC-rich
sequences in the Akap12a promoter were shown to undergo
hypermethylation and gene silencing in various cancer cell lines; in
contrast, the Akap12b promoter exhibited less gene silencing in
cancer cells [34,39,40]. A subsequent study demonstrated a
methylation-independent mechanism for Akap12a promoter si-
lencing through the recruitment of HDAC1 [49]. More recently,
the anti-proliferative agent dexamethasone was shown to weakly
(2-fold) activate the Akap12a promoter without influencing
Akap12b promoter activity, though no glucocorticoid responsive
elements were reported [37]. We provide evidence here for a
conserved RARE in the upstream Akap12b promoter region that is
weakly responsive to retinoids. The DR-2 RARE in the Akap12b
promoter is very similar to that of the known retinoid-response
gene Ca2 [30], which similarly exhibits weak activation with atRA
stimulation (Figure 3B). Although we could not show consistent
binding of a retinoic acid receptor to the RARE containing region,
several lines of evidence suggest that retinoid receptors target this
or perhaps a more distal Akap12b promoter region. First,
actinomycin D experiments showed that the induction of Akap12b
by atRA proceeds in a RNA polymerase II-dependent manner.
Second, three synthetic retinoids that directly bind and activate
retinoid receptors each induced Akap12bmRNA expression. Third,
a ChIP assay revealed retinoid-mediated enrichment of acetylated
histones in the region encompassing the Akap12b RARE. The
weak activation of Akap12b promoter with retinoid treatment may
imply the absence of key cofactor modifications needed to fully
activate the promoter. Alternatively, there may exist remote
regulatory elements, as reviewed elsewhere [50], controlling
retinoid-mediated transcription of Akap12b from a distance.
Methods in bacterial artificial chromosome transgenic mouse
technology and related recombineering would be ideal approaches
to address the latter possibility. Whatever the full extent of the
mechanism(s) may be, this study clearly demonstrates that the
increase in Akap12 with retinoid treatment proceeds through
Akap12b.
AKAP12 is not the only AKAP shown to suppress SMC growth
responses. AKAP5 (aka AKAP79/AKAP75/AKAP150 in human,
bovine, rat respectively) was previously demonstrated to inhibit
SMC growth in vitro and, similar to our findings here, AKAP5
stimulated CREB-dependent transcriptional activity [51]. More-
over, local delivery of AKAP5 to the balloon-injured vessel wall
reduced the extent of neointimal burden [51]. Since, as shown in
this report, AKAP12 is reduced in human and rodent vascular
lesions, one would not expect a compensatory, confounding
influence of AKAP12 on AKAP5-mediated effects. In this context,
there is similarity in key amino acid sequences between AKAP12
and AKAP5 [52]. Moreover, we have observed AKAP12 and
AKAP5 share similar flanking genes suggesting that these two
AKAPs are paralogs related via a segmental chromosomal
duplication (Figure S5). Despite the functional and genomic
similarities between AKAP12 and AKAP5, only AKAP12b is
induced with retinoids as we were unable to show similar
induction of AKAP5 (data not shown).
In summary, the results of this report document retinoid-
induced stimulation of a specific AKAP12 isoform which exhibits
Figure 7. AKAP12 expression is reduced in human neointimal tissue. Serial sections of two independent atherosclerotic coronary vessels
(panels A–C and D–F) stained for AKAP12 (panels A, D), CNN1 (panels B, E) and Ham56 (panels C, F). The red stain reveals positive immunoreactivity
confined largely to the tunica media (AKAP12 and CNN1 indicated with a large arrow) or neointima (Ham56, indicated with small arrow). The
neointima is labeled with an asterisk in each panel. Similar results have been found in multiple independent coronary arteries of varying
atherosclerotic severity. Magnifications are 2006.
doi:10.1371/journal.pone.0018538.g007
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signaling. Future studies should evaluate the extent of neointimal
formation and the effects of retinoids in suppressing such growth in
mice where the Akap12 gene is genetically deleted [26]. Finally,
effects of retinoids on AKAP12b expression should be evaluated in
other disease contexts where cell proliferation is manifest (e.g.,
cancer).
Materials and Methods
Treatment of cells or animals with retinoids
Rat pulmonary artery SMC (PAC1) were grown and main-
tained as described previously [53]. Primary-derived rat aortic
SMC (RASMC) were obtained from adult thoracic aorta of male
Sprague-Dawley rats as described [54], grown in Dulbecco’s
modified Eagles Medium supplemented with 10% fetal bovine
serum (FBS), and used between passage number 10–20. Human
coronary artery SMC (hCASMC) were obtained from Cascade
Biologics (Portland, OR) and grown in commercially-supplied
growth medium per manufacturer’s specifications. In all SMC
cultures, we routinely validate their phenotype with a panel of
SMC-restricted markers, including the SMC-restricted myocardin
transcription factor [55,56]. For retinoid stimulation, cells were
synchronized for 24 hr in 0.25% FBS and then stimulated in fresh
medium containing 0.25% FBS for the indicated times with
2610
26 M of atRA, 13-cis RA, or 1 mM of one of three synthetic
retinoids (AM80, BMY-46561, RAR agonists and BMS-188649,
an RXR agonist). Control cells received 0.1% dimethylsulfoxide
(diluent for retinoids) in medium containing 0.25% FBS. For in
vivo experiments, we introduced either 10 mg/kg atRA in corn oil
or an equivalent volume (,50 ml) of corn oil alone by oral gavage
to adult male FVB/N mice (n=4 per treatment) and collected
blood by intra-cardiac puncture 6 hr later for the determination of
serum levels of atRA and its two major stereoisomers (9-cis RA
and 13-cis RA) by HPLC as described previously [11]. The same
mice were euthanized 18 hr later and aortas (stripped of
endothelium and adventitia) harvested for total RNA isolation
(as above) and RT-PCR with isoform-specific primers as described
[29].
cDNA cloning, Northern blotting, and RT-PCR
A rat-specific Akap12 probe common to all three Akap12
isoforms was PCR amplified from PAC1 cDNA using the
following specific primers containing a 5 bp clamp and restriction
sites (underlined): forward 59- gatacggatccccaggatggggaagctga -39
and reverse, 59- gatacaagcttttccttgctctcttcttgg -39 amplifying a
323 bp fragment of Akap12. A human-specific AKAP12b probe was
PCR amplified from human coronary artery SMC (HCASMC)
cDNA using the following specific primers: forward, 59- gattag-
gatccccgctgaccactcacagag -39 and reverse, 59- gattgaagctttgtgatggt-
gatggtcccc -39 amplifying a 421 bp probe. Rat Akap12 isoform
specific probes were PCR amplified as follows: for Akap12a
(forward 59- gataggtcgacgggagtagaagagccactg -39 and reverse, 59-
cactcaagctttcaacgacttcttcctcc -39 amplifying a 281 bp probe from
GenBank Accession number AY695056); for Akap12b (forward 59-
gtatgtctagaatgctctgaggatagttagg -3 and reverse, 59- ctat-
gaagcttctgtccaactgtgatggta -39 amplifying a 156 bp probe from
GenBank Accession number AY695057); and for Akap12c
(forward 59- gataggtcgacaggcttggtagtttcgaagg -39 and reverse, 59-
gatacaagctttctcgctgtccaagggaag -39 amplifying a 115 bp probe
from GenBank Accession number AY695058). Total RNA was
isolated from control and retinoid-stimulated cells using TRIzol
and fractionated in a 1.2% agarose gel, blotted to nitrocellulose,
hybridized with
32P-dCTP-labeled probes, washed and exposed to
Kodak X-ray film as described [21]. Alternatively, total RNA from
retinoid-treated PAC1 SMC was analyzed by quantitative RT-
PCR with BioRad’s MyiQ icycler with primers (designed with
Beacon Software, BioRad) specific to human AKAP12b (forward
59- ttggcaggcaggagactagg -39 and reverse, 59 - tcgtgaacaaccgct-
gacttag -39 amplifying a 187 bp product).
Adenoviral construction
Full-length Akap12b cDNA with a carboxy-terminal FLAG
epitope and LacZ were each cloned into pENTR/D-TOPO
(Invitrogen) and then recombined into pAd/plDEST (Invitrogen)
using LR clonase to create the Ad-AKAP12b or Ad-LacZ
adenoviral constructs as described previously [48]. Viral produc-
tion and titering were also done as described [48].
Western blotting and R2 overlay assays
PAC1 SMC were synchronized with 0.25% FBS for 24 hr
before stimulation with either 2610
26 M atRA or 0.1% DMSO
and protein extracted for Western blotting as described [48].
Primary antibodies to AKAP12 [22] (1:2000 dilution), smooth
muscle calponin (hCP, Sigma; 1:10,000 dilution) or alpha tubulin
(T5168, Sigma; 1:2000) were applied to membranes followed by
species-appropriate HRP-conjugated secondary antibodies. To
evaluate the interaction of AKAP12 with the regulatory subunit of
PKA, PAC1 SMC were stimulated with 2610
26 M atRA or 0.1%
DMSO for 12 and 24 hr and 75 mg total protein resolved in a
large format 5% SDS-PAGE gel. The gel was then electro-blotted
to a PVDF (Immobilon-P) membrane and dried for a radiolabeled
RII overlay as described [57].
Immunofluorescence microscopy
Cells were grown on glass chamber slides (Labtek), treated for
retinoid stimulation as above, and at the indicated times, fixed,
processed, and visualized with a fluorescence microscope as
previously described [58]. Primary antibodies used were polyclon-
al rabbit anti-AKAP12 [22] and mouse anti-PKA RII alpha (BD
Transduction Laboratories, Cat # 612242).
Bioinformatics
Identification of a conserved RARE around the promoter of
Akap12b isoform was performed using VISTA (http://www-gsd.
lbl.gov/vista/index.shtml)(citation) by searching for pairs of
consensus half sites (RGGTCA) and characterized variants
situated within several nucleotides of each other that are conserved
in sequence and relative position within a 20 kb window centered
on the human, rat, and mouse Akap12b promoters [4].
Cell transfections and reporter assay
To test and compare the Akap12b RARE for functionality,
oligonucleotide primers comprising 3x multimerized RAREs from
Akap12b, Rarb, or the retinoid-response gene, carbonic anhydrase
(Ca2) were inserted upstream of the minimal thymidine kinase
promoter of tk-luciferase. PAC-1 SMC were transfected with the
indicated construct, made quiescent for 24 hours using 0.25%
FBS-containing DMEM, and subsequently stimulated with
2610
26 M atRA for 24 hours. Dual luciferase assays were
performed as previously described [29]. Data shown are
representative of at least three independent experiments. Error
bars represent the standard deviation from the mean. Data were
analyzed by one-way ANOVA and Tukey’s post-hoc test using
GraphPad Prism software. A probability value less than 0.05 was
considered statistically significant. In some experiments, similar
luciferase assays were done in PAC1 SMC using a CREB reporter
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empty control vector or one carrying the AKAP12b open reading
frame.
Cell transduction and growth assay
Stable cell lines expressing doxycycline-inducible, Myc-tagged
AKAP12b were generated using the T-Rex System (Invitrogen) in
PAC1 SMC according to the manufacturer’s specifications. To
induce expression of AKAP12b, cells were treated every other day
with 1 mg/ml doxycycline (Sigma) and levels of AKAP12b
measured with a Myc antibody. HCASMC were grown to
subconfluence in 6-well dishes and transduced with 300 infectious
units per cell (ifu/cell) of either CMV-driven LacZ (Ad-LacZ) or
CMV-driven AKAP12b (Ad-AKAP12b) in 2% FBS as described
[48]. Following overnight culture in 2% FBS, culture medium was
changed and replaced with 0.25% FBS for 24 hr to synchronize
the cells. Cells were then stimulated with full growth medium and
the number of trypan blue negative cells manually counted with a
hemocytometer. At least three independent measures per time
point were made in two independent experiments. Results are
presented as the average of three replicates from one experiment
6 the standard error of the mean.
Ligation injury model
Male C57BL/B6 mice (30 g) were subject to partial ligation of
the left carotid artery [33] and FVB/N mice were injured by
complete ligation of the common carotid artery [59]. One and
three weeks after injury, animals were perfusion fixed with neutral
buffered formalin, vessels removed and processed, and sections
(5 mm) of injured arteries distal to the ligature stained by
immunohistochemistry with a polyclonal antibody to AKAP12
[22] or an antibody to Ki-67 to detect proliferating cells of the
vessel wall. All animal studies were approved by the University of
Rochester’s Institutional Animal Care and Use Committee.
Immunohistochemistry
Mouse vessels were fixed in 4% buffered paraformaldehyde and
paraffin embedded. Samples of human coronary vessels with
variable degrees of atherosclerosis were obtained from archived
tissues in the University of Rochester Medical Center’s Pathology
Department. All tissues were sectioned at 5 micron thickness and
slides were deparaffinized and rehydrated to PBS (pH, 7.4).
Endogenous peroxidase activity was quenched using 3% aqueous
hydrogen peroxide for 10 minutes and antigen retrieval was
performed (for CNN1) utilizing heat induced epitope retrieval in
0.05% citraconic anhydride as described [60]. Primary antibodies
(and their dilution) were as follows: rabbit polyclonal anti-AKAP12
(1:500), anti-CNN1 (DAKO; 1:1000), Ham56 (DAKO; 1:1000),
and Ki-67 (DAKO, 1:100). Appropriate secondary biotinylated
antibodies (Vector BA-2000, BA-1000, or DAKO rabbit anti-rat
for Ki-67) were applied for 30 minutes at room temperature
following washes in TBST. Immunoreactive signals were revealed
by a 30 minute dark exposure to either alkaline phosphatase
(Vector AK-5000) followed by Vector Red (Vector SK-5100)
chromagen or horseradish peroxidase (Vector PK-6100) followed
by diaminobenzidine chromagen. Specific immunoreactive prod-
uct was indicated by inclusion of control isotype-matched IgG on
adjacent sections that were handled in exactly the same manner as
those stained with primary antibodies.
Supporting Information
Figure S1 A, PAC1 SMC were treated with 1 mM AM80 for the
indicated times or DMSO diluent and Akap12b mRNA measured
by qRT-PCR (n=3). B, PAC1 SMC were treated with 1 mM
AM80 for 6 hr and immediately thereafter were exposed to 1 mg/
ml actinomycin D or equal amount of water for the indicated
times and Akap12b mRNA measured by qRT-PCR as in panel A.
Akap12b mRNA was normalized to internal control Gapdh with the
control (DMSO or 0 h) ratio set to a value of 1.
(TIF)
Figure S2 Extracts of PAC1 SMC were treated with DMSO or
the synthetic retinoid, AM80 (1 mM), for 24 hrs and total protein
analyzed for AKAP12, ACTA2, CNN1 and TUBA1 (control)
proteins.
(TIF)
Figure S3 A, PAC1 SMC were co-transfected with a CREB
reporter and either an empty vector or an AKAP12b expression
plasmid to assess CREB activity in a luciferase assay. Results are
expressed as normalized luciferase (see Methods). B, PAC1 SMC
were co-transfected with EGFP (control) 6 AKAP12b and
phosphorylation of VASP assessed by immunoblotting.
(TIF)
Figure S4 Non-immunogenic IgG control antisera was applied
to uninjured right carotid (A), 7 day injured left carotid (B), and 21
day injured left carotid (C). Panels D-F represent AKAP12
staining of uninjured carotid (D) and femoral (E) artery or a 7 day
complete ligation injured carotid artery (F). Note loss of AKAP12
staining in the media of the injured vessel (F) as compared to
normal vessels (D,E).
(TIF)
Figure S5 Schematic shows evidence of segmental chromosomal
duplication with percent amino acid homologies between AKAP5
and AKAP12 and their paralogous flanking genes.
(TIF)
Acknowledgments
We thank Dr. Leon Metlay for kindly providing the samples of fixed
human coronary artery specimens and Dr. Vyacheslav (Slava) Korshunov
for sections of partially ligated mouse carotid artery.
Author Contributions
Conceived and designed the experiments: JWS JMM. Performed the
experiments: JWS XL T-HL QS CMK MAG OJS WSB DWC. Analyzed
the data: JWS XL T-HL WSB DWC IHG JMM. Contributed reagents/
materials/analysis tools: WSB DWC IHG. Wrote the paper: JMM.
References
1. Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular
smooth muscle cell differentiation in development and disease. Physiol Rev 84:
767–801.
2. Miano JM, Berk BC (2000) Retinoids: Versatile biological response modifiers of
vascular smooth muscle phenotype. Circ Res 87: 355–362.
3. Lippman SM, Heyman RA, Kurie JM, Benner SE, Hong WK (1995) Retinoids
and chemoprevention: clinical and basic studies. J Cell Biochem 22: 1–10.
4. Streb JW, Miano JM (2003) Retinoids: pleiotropic agents of therapy for vascular
diseases? Current Drug Targets 3: 31–57.
5. Miano JM, Topouzis S, Majesky MW, Olson EN (1996) Retinoid receptor
expression and all-trans retinoic acid-mediated growth inhibition in vascular
smooth muscle cells. Circulation 93: 1886–1895.
6. Haxsen V, Adam-Stitah S, Ritz E, Wagner J (2001) Retinoids inhibit the actions
of angiotensin II on vascular smooth muscle cells. Circ Res 88: 637–644.
Retinoids Induce AKAP12b
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e185387. Kosaka C, Sasaguri T, Komiyama Y, Takahashi H (2001) All-trans retinoic acid
inhibits vascular smooth muscle cell proliferation targeting multiple genes for
cyclins and cyclin-dependent kinases. Hypertens Res 24: 579–588.
8. Pakala R, Benedict CR (2000) RAR c agonists inhibit proliferation of vascular
smooth muscle cells. J Cardiovasc Pharmacol 35: 302–308.
9. Wang S, Wright G, Geng W, Wright GL (1997) Retinol influences contractile
function and exerts an anti-proliferative effect on vascular smooth muscle cells
through an endothelium-dependent mechanism. Pflugers Arch 434: 669–677.
10. Wright G, Wang S, Bailey G, Reichenbecher V, Wright GL (1996) Effect of
retinoic acid on contractile competence of vascular smooth muscle. Am J Physiol
270: H1363–H1370.
11. Miano JM, Kelly LA, Artacho CA, Nuckolls TA, Piantedosi R, et al. (1998) all-
trans-retinoic acid reduces neointimal formation and promotes favorable
geometric remodeling of the rat carotid artery after balloon withdrawal injury.
Circulation 98: 1219–1227.
12. Neuville P, Yan Z, Gidlo ¨f A, Pepper MS, Hansson GK, et al. (1999) Retinoic
acid regulates arterial smooth muscle cell proliferation and phenotypic features
in vivo and in vitro through an RARa-dependent signaling pathway.
Arterioscler Thromb Vasc Biol 19: 1430–1436.
13. DeRose JJ Jr., Madigan J, Umana JP, Prystowsky JH, Nowygrod R, et al. (1999)
Retinoic acid suppresses intimal hyperplasia and prevents vessel remodeling
following arterial injury. Cardiovasc Surg 7: 633–639.
14. Wiegman PJ, Barry WL, McPherson JA, McNamara CA, Gimple LW, et al.
(2000) All-trans-retinoic acid limits restenosis after balloon angioplasty in the
focally atherosclerotic rabbit: a favorable effect on vessel remodeling.
Arterioscler Thromb Vasc Biol 20: 89–95.
15. Chen J, He B, Zheng D, Zhang S, Liu J, Zhu S (1999) All-trans retinoic acid
reduces intimal thickening after balloon angioplasty in atherosclerotic rabbits.
Chin Med J 112: 121–123.
16. Leville CD, Dassow MS, Seabrook GR, Jean-Claude JM, Towne JB, et al.
(2000) All-trans-retinoic acid decreases vein graft intimal hyperplasia and matrix
metalloproteinase activity in vivo. J Surg Res 90: 183–190.
17. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, et al. (2002) Kruppel-
like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II
signaling and an essential regulator of cardiovascular remodeling. Nat Med 8:
856–863.
18. Fujiu K, Manabe I, Ishihara A, Oishi Y, Iwata H, et al. (2005) Synthetic retinoid
Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima
formation by inhibiting KLF5. Circ Res 97: 1132–1141.
19. Haraguchi G, Suzuki JI, Kosuge H, Ogawa M, Koga N, et al. (2006) A new
RXR agonist, HX630, suppresses intimal hyperplasia in a mouse blood flow
cessation model. J Mol Cell Cardiol 41: 885–892.
20. McKenna NJ, O’Malley BW (2002) Combinatorial control of gene expression by
nuclear receptors and coregulators. Cell 108: 465–474.
21. Chen J, Maltby KM, Miano JM (2001) A novel retinoid-response gene set in
vascular smooth muscle cells. Biochem Biophys Res Comm 281: 475–482.
22. Lin X, Tombler E, Nelson PJ, Ross M, Gelman IH (1996) A novel src-a n dras-
suppressed protein kinase C substrate associated with cytoskeletal architecture.
J Biol Chem 271: 28430–28438.
23. Gordon T, Grove B, Loftus J, O’Toole T, McMillian R, et al. (1992) Molecular
cloning and preliminary characterization of a novel cytoplasmic antigen
recognized by myasthenia gravis sera. J Clin Invest 90: 992–999.
24. Gelman IH (2002) The role of SSeCKS/Gravin/AKAP12 scaffolding proteins
in the spatiotemporal control of signaling pathways in oncogenesis and
development. Front Biosci 7: 1782–1797.
25. Wong W, Scott JD (2004) AKAP signalling complexes: focal points in space and
time. Nat Rev Mol Cell Biol 5: 959–970.
26. Akakura S, Huang C, Nelson PJ, Foster B, Gelman IH (2008) Loss of the ssecks/
gravin/akap12 gene results in prostatic hyperplasia. Cancer Res 68: 5096–5103.
27. Gelman IH, Tombler E, Vargas J Jr. (2000) A role for SSeCKS, a major protein
kinase C substrate with tumor suppressor activity, in cytoskeletal architecture,
formation of migratory processes, and cell migration during embryogenesis.
Histochem J 32: 13–26.
28. Coats SR, Covington JW, Su M, Pablon-Pena LM, Eren M, et al. (2000)
SSeCKS gene expression in vascular smooth muscle cells: regulation by
angiotension II and as potential role in the regulation of PAI-1 gene expression.
J Mol Cell Cardiol 32: 2207–2219.
29. Streb JW, Kitchen CM, Gelman IH, Miano JM (2004) Multiple promoters
direct expression of three AKAP12 isoforms with distinct tissue and subcellular
distribution profiles. J Biol Chem 279: 56014–56023.
30. Que ´lo I, Jurdic P (2000) Differential regulation of the carbonic anhydrase II gene
expression by hormonal nuclear receptors in monocytic cells: identification of
the retinoic acid response element. Biochem Biophys Res Comm 271: 481–491.
31. Taske ´n K, Aandahl EM (2004) Localized effects of cAMP mediated by distinct
routes of protein kinase A. Physiol Rev 84: 137–167.
32. Choi M-C, Jong H-S, Kim TY, Song S-H, Lee DS, et al. (2004) AKAP12/
Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and
shows growth suppressor activity. Oncogene 23: 7095–7103.
33. Korshunov VA, Berk BC (2003) Flow-induced vascular remodeling in the
mouse: a model for carotid intima-media thickening. Arterioscler Thromb Vasc
Biol 23: 2185–2191.
34. Goeppert B, Schmezer P, Dutruel C, Oakes C, Renner M, et al. (2010) Down-
regulation of tumor suppressor A kinase anchor protein 12 in human
hepatocarcinogenesis by epigenetic mechanisms. Hepatology 52: 2023–2033.
35. Stolle K, Weitkamp B, Rauterberg J, Lorkowski S, Cullen P (2004) Laser
microdissection-based analysis of mRNA expression in human coronary arteries
with intimal thickening. J Histochem Cytochem 52: 1511–1518.
36. Liu Y, Gao L, Gelman IH (2006) SSeCKS/Gravin/AKAP12 attenuates
expression of proliferative and angiogenic genes during suppression of v-Src-
induced oncogenesis. BMC Cancer 6: 105-.
37. Liu H, Huang X, Wang H, Shen A, Cheng C (2009) Dexamethasone inhibits
proliferation and stimulates SSeCKS expression in C6 rat glioma cell line. Brain
Res 1265: 1–12.
38. Xia W, Unger P, Miller L, Nelson J, Gelman IH (2001) The src-suppressed C
kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
Cancer Res 61: 5644–5651.
39. Flotho C, Paulun A, Batz C, Niemeyer CM (2007) AKAP12, a gene with tumour
suppressor properties, is a target of promoter DNA methylation in childhood
myeloid malignancies. Br J Haematol 138: 644–650.
40. Jo U, Whang YM, Kim HK, Kim YH (2006) AKAP12alpha is associated with
promoter methylation in lung cancer. Cancer Res Treat 38: 144–151.
41. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, et al.
(1997) Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell
proliferation induced by vascular injury. Nat Med 7: 775–779.
42. Venance SL, Bennett BM, Pang SC (1993) Forskolin and isoproterenol effect
responses on epidermal growth factor induced DNA synthesis in aortic smooth
muscle cells. Can J Physiol Pharmacol 71: 800–805.
43. Indolfi C, Di Lorenzo E, Rapacciuolo A, Stingone AM, Stabile E, et al. (2000) 8-
chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima
formation induced by balloon injury in vivo. J Am Coll Cardiol 36: 288–293.
44. Tao J, Shumay E, McLaughlin S, Wang H-Y, Malbon CC (2006) Regulation of
AKAP-membrane interactions by calcium. J Biol Chem 281: 23932–23944.
45. Yan X, Walkiewicz M, Carlson J, Leiphon L, Grove B (2009) Gravin dynamics
regulates the subcellular distribution of PKA. Exp Cell Res 315: 1247–1259.
46. Ichiki T (2006) Role of cAMP response element binding protein in
cardiovascular remodeling: good, bad, or both? Arterioscler Thromb Vasc Biol
26: 449–455.
47. Nagpal S (2004) Retinoids: inducers of tumor/growth suppressors. J Invest
Dermatol 123: xx–xxi.
48. Streb JW, Miano JM (2005) AKAP12a: an atypical serum response factor-
dependent target gene. J Biol Chem 280: 4125–4134.
49. Bu Y, Gelman IH (2007) v-Src-mediated down-regulation of SSeCKS metastasis
suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3
complex. J Biol Chem 282: 26725–26739.
50. Long X, Miano JM (2007) Remote control of gene expression. J Biol Chem 282:
15941–15945.
51. Indolfi C, Stabile E, Coppola C, Gallo A, Perrino C, et al. (2001) Membrane-
bound protein kinase A inhibits smooth muscle cell proliferation in vitro and in
vivo by amplifying cAMP-protein kinase A signals. Circ Res 88: 319–324.
52. Wang H-Y, Tao J, Shumay E, Malbon CC (2006) G-protein-coupled receptor-
associated A-kinase anchoring proteins: AKAP79 and AKAP250 (gravin).
Eur J Cell Biol 85: 643–650.
53. Firulli AB, Han D, Kelly-Roloff L, Koteliansky VE, Schwartz SM, et al. (1998)
A comparative molecular analysis of four rat smooth muscle cell lines. In Vitro
Cell Dev Biol 34: 217–226.
54. Firulli AB, Miano JM, Bi W, Johnson AD, Casscells W, et al. (1996) Myocyte
enhancer binding factor-2 expression and activity in vascular smooth muscle
cells: association with the activated phenotype. Circ Res 78: 196–204.
55. Wang D-Z, Chang PS, Wang Z, Sutherland L, Richardson JA, et al. (2001)
Activation of cardiac gene expression by myocardin, a transcriptional cofactor
for serum response factor. Cell 105: 851–862.
56. Chen J, Kitchen CM, Streb JW, Miano JM (2002) Myocardin: a component of a
molecular switch for smooth muscle differentiation. J Mol Cell Cardiol 34:
1345–1356.
57. Carr DW, Hausken ZE, Fraser IDC, Stofko-Hahn RE, Scott JD (1992)
Association of the type II cAMP-dependent protein kinase with a human thyroid
RII-anchoring protein: cloning and characterization of the RII-binding domain.
J Biol Chem 267: 13376–13382.
58. Sun Q, Chen G, Streb JW, Long X, Yang Y, et al. (2006) Defining the
mammalian CArGome. Genome Res 16: 197–207.
59. Kumar A, Lindner V (1997) Remodeling with neointima formation in the mouse
carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17:
2238–2244.
60. Namimatsu S, Ghazizadeh M, Sugisaki Y (2005) Reversing the effects of
formalin fixation with citraconic anhydride and heat: a universal antigen
retrieval method. J Histochem Cytochem 53: 3–11.
Retinoids Induce AKAP12b
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18538